{
  "docId": "019de077-4c75-7299-85f2-8570aa012761",
  "docSlug": "bc27eff688e591dce79cc29b4a79cc4b",
  "documentTitle": "Starboard Value | Activist Presentation Deck | 74 slides",
  "authorId": "starboard-value",
  "authorName": "Starboard Value",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2024-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 74,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 44,
  "notes": "The chart uses a dashed box to highlight PFE and a dashed red line to indicate the peer median of 46 drugs.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-4c75-7299-85f2-8570aa012761/12",
  "deckHref": "/decks/019de077-4c75-7299-85f2-8570aa012761",
  "deckJsonHref": "/decks/019de077-4c75-7299-85f2-8570aa012761.json",
  "deckAnchorHref": "/decks/019de077-4c75-7299-85f2-8570aa012761#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.12,
        "x": 0.26,
        "y": 0.28
      },
      "kind": "callout",
      "text": "Pfizer had a healthy pipeline of assets in clinical development",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb8e38bf-f681-4760-8e4d-03ec3197699c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Number of New Drugs in Pipeline as of January 2, 2019",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f9dabe5-932f-4b76-ae04-1ba78961a372",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.02,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "Source: Wall Street Research. Starboard has identified BMY, AZN, JNJ, NOVN, ROG, MRK, SAN, GILD, ABBV, AMGN, LLY, NVO, and GSK as the relevant peer set...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07e993fa-a109-49fe-b256-57f5ef686aeb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.24,
        "x": 0.38,
        "y": 0.83
      },
      "kind": "legend",
      "text": "Phase 1, Phase 2, Phase 3, NDA",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6f41de4-caa1-47b0-9b00-602cf2c7b92e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "At the beginning of 2019, Pfizer had the fourth-most-number of new drugs in development out of its peer group.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "965f267c-491a-49c2-864c-ce4c60fdf101",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "At the Beginning of 2019, Pfizer Had a Robust New Product Pipeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "239ceff6-e4a7-4d37-9ef4-a1ec919b147a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "peer-benchmark",
      "slug": null,
      "matchId": "90cf13e9-e6af-4ef5-b687-72b9490bcbcd",
      "evidence": "Comparison of Pfizer's pipeline against a defined peer group.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 30,
      "from": 11,
      "beatId": "e3d3e281-b7d2-40bf-bf10-c286405c0d64",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document agitates the problem by highlighting Pfizer's lack of internal innovation, failed products, and poor capital allocation.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 12,
      "name": "Iceberg",
      "slug": "10-iceberg",
      "bestFor": "Consulting, complex problem solving, organizational change",
      "matchId": "5022ccdf-4dc3-4ffa-8bea-f9ccda118289",
      "evidence": "The document presents a series of slides exposing contradictions between Pfizer's claims and actual results, revealing the iceberg-like issues beneath the surface.",
      "position": 0,
      "objective": "What are the reasons behind Pfizer's lack of internal innovation?",
      "structure": "The Symptom (Visible) -> The System (Hidden) -> The Root Cause",
      "confidence": 0.7,
      "description": "Reveal that the visible problem is merely a symptom of a deeper root cause"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}